Related Experiment Videos
Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin
Abstract:
The current status of three drugs of clinical interest to the National Cancer Institute is reviewed. m-AMSA, a drug with a wide spectrum of activity in murine tumors, is now in phase II trial and has shown itself to have a high order of activity in acute nonlymphocytic leukemia. Dihydroxyanthracenedione, a compound with some of the characteristics of anthracyclines but with no cardiac toxicity in animal toxicology studies, is in phase I evaluation. Deoxycoformycin, an adenosine analog which is a potent inhibitor of adenosine deaminase, has shown moderate activity in acute leukemia patients in phase I trials, and has the potential to produce synergistic antitumor toxicity when used with arabinofuranosyladenine.
Insights
Three novel cancer drugs are in clinical trials. m-AMSA shows high activity in acute nonlymphocytic leukemia, dihydroxyanthracenedione has no cardiac toxicity, and deoxycoformycin may enhance chemotherapy effectiveness.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Review of National Cancer Institute's drugs in clinical trials.
- Focus on three agents with potential anti-cancer activity.
Purpose of the Study:
- To update on the clinical status of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
- To highlight their potential in cancer treatment.
Main Methods:
- Phase II trial of m-AMSA.
- Phase I evaluation of dihydroxyanthracenedione.
- Phase I trials of deoxycoformycin.
Main Results:
- m-AMSA demonstrates high activity in acute nonlymphocytic leukemia.
- Dihydroxyanthracenedione shows promise with no observed cardiac toxicity in preclinical studies.
- Deoxycoformycin exhibits moderate activity in leukemia and potential for synergistic effects.
Conclusions:
- m-AMSA is a promising agent for acute nonlymphocytic leukemia.
- Dihydroxyanthracenedione represents a potentially safer anthracycline-like compound.
- Deoxycoformycin offers therapeutic potential, especially in combination therapies.